NASDAQ:IGMS IGM Biosciences (IGMS) Stock Forecast, Price & News $10.59 -3.01 (-22.13%) (As of 06/5/2023 ET) Add Compare Share Share Today's Range$10.51▼$13.5650-Day Range$9.98▼$17.2752-Week Range$9.74▼$28.20Volume559,819 shsAverage Volume225,582 shsMarket Capitalization$456.22 millionP/E RatioN/ADividend YieldN/APrice Target$29.63 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability IGM Biosciences MarketRank™ ForecastAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside179.7% Upside$29.63 Price TargetShort InterestBearish23.65% of Float Sold ShortDividend StrengthN/ASustainability-1.08Upright™ Environmental ScoreNews Sentiment1.46Based on 6 Articles This WeekInsider TradingSelling Shares$60,394 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($5.97) to ($5.36) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.56 out of 5 starsMedical Sector108th out of 986 stocksPharmaceutical Preparations Industry39th out of 478 stocks 4.3 Analyst's Opinion Consensus RatingIGM Biosciences has received a consensus rating of Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $29.63, IGM Biosciences has a forecasted upside of 179.7% from its current price of $10.59.Amount of Analyst CoverageIGM Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted23.65% of the float of IGM Biosciences has been sold short.Short Interest Ratio / Days to CoverIGM Biosciences has a short interest ratio ("days to cover") of 18, which indicates bearish sentiment.Change versus previous monthShort interest in IGM Biosciences has recently increased by 2.46%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldIGM Biosciences does not currently pay a dividend.Dividend GrowthIGM Biosciences does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIGM Biosciences has received a 71.95% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Clinical research services for infectious diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for IGM Biosciences is -1.08. Previous Next 3.6 News and Social Media Coverage News SentimentIGM Biosciences has a news sentiment score of 1.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for IGM Biosciences this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for IGMS on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat Follows1 people have added IGM Biosciences to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IGM Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $60,394.00 in company stock.Percentage Held by Insiders55.96% of the stock of IGM Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions41.41% of the stock of IGM Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for IGM Biosciences are expected to grow in the coming year, from ($5.97) to ($5.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IGM Biosciences is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IGM Biosciences is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIGM Biosciences has a P/B Ratio of 1.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About IGM Biosciences (NASDAQ:IGMS) StockIGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.Read More Receive IGMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IGM Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address IGMS Stock News HeadlinesJune 5, 2023 | msn.comWedbush Reiterates IGM Biosciences (IGMS) Outperform RecommendationJune 1, 2023 | finance.yahoo.comIGM Biosciences to Present at the Jefferies Healthcare ConferenceJune 6, 2023 | Legacy Research (Affiliate) (Ad)“One-Stock Millionaire” IGNORES 99.9% of the MarketDuring the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.May 31, 2023 | finance.yahoo.comIGM Biosciences Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid ArthritisMay 30, 2023 | finance.yahoo.comIGM Biosciences to Host Conference Call and Webcast to Provide IGM-8444 Clinical UpdateMay 27, 2023 | americanbankingnews.comIGM Biosciences, Inc. (NASDAQ:IGMS) Insider Chris H. Takimoto Sells 1,259 SharesMay 27, 2023 | americanbankingnews.comIGM Biosciences, Inc. (NASDAQ:IGMS) Receives $29.78 Average Price Target from AnalystsMay 24, 2023 | americanbankingnews.comIGM Biosciences (NASDAQ:IGMS) Trading 8.6% Higher June 6, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 18, 2023 | americanbankingnews.comIGM Biosciences (NASDAQ:IGMS) Shares Down 6.5% After Analyst DowngradeMay 17, 2023 | msn.comJP Morgan Maintains IGM Biosciences (IGMS) Neutral RecommendationMay 17, 2023 | americanbankingnews.comGuggenheim Lowers IGM Biosciences (NASDAQ:IGMS) Price Target to $38.00May 16, 2023 | msn.comRBC Capital Maintains IGM Biosciences (IGMS) Sector Perform RecommendationMay 16, 2023 | msn.comWedbush Maintains IGM Biosciences (IGMS) Outperform RecommendationMay 15, 2023 | markets.businessinsider.comAnalyst Expectations for IGM Biosciences's FutureMay 15, 2023 | americanbankingnews.comIGM Biosciences (NASDAQ:IGMS) Price Target Cut to $17.00May 12, 2023 | finanznachrichten.deIGM Biosciences, Inc.: IGM Biosciences Announces First Quarter 2023 Financial Results and Provides Corporate UpdateMay 12, 2023 | msn.comRecap: IGM Biosciences Q1 EarningsMay 12, 2023 | finance.yahoo.comIGM Biosciences Announces First Quarter 2023 Financial Results and Provides Corporate UpdateMay 12, 2023 | finance.yahoo.comIGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Lags Revenue EstimatesApril 30, 2023 | americanbankingnews.comIGM Biosciences, Inc. (NASDAQ:IGMS) Given Consensus Rating of "Moderate Buy" by BrokeragesApril 28, 2023 | finance.yahoo.comBullish IGM Biosciences, Inc. (NASDAQ:IGMS) insiders filled their treasuries with US$1.6m worth of stock over last yearApril 19, 2023 | finance.yahoo.comIGM Biosciences to Present at the Stifel 2023 Targeted Oncology DaysApril 15, 2023 | americanbankingnews.comIGM Biosciences (NASDAQ:IGMS) Trading Up 18.3%April 13, 2023 | finance.yahoo.comIGM Biosciences Announces Six Presentations at the American Society for Cancer Research Annual Meeting 2023April 8, 2023 | americanbankingnews.comIGM Biosciences, Inc. (NASDAQ:IGMS) Insider George Gauthier Sells 935 SharesApril 8, 2023 | americanbankingnews.comQ1 2023 Earnings Forecast for IGM Biosciences, Inc. Issued By HC Wainwright (NASDAQ:IGMS)See More Headlines IGMS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IGMS Company Calendar Last Earnings3/30/2023Today6/05/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IGMS CUSIPN/A CIK1496323 Webigmbio.com Phone650-965-7873FaxN/AEmployees192Year Founded2010Price Target and Rating Average Stock Price Forecast$29.63 High Stock Price Forecast$55.00 Low Stock Price Forecast$17.00 Forecasted Upside/Downside+179.7%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($5.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-221,100,000.00 Net Margins-14,363.10% Pretax Margin-14,357.64% Return on Equity-74.30% Return on Assets-43.54% Debt Debt-to-Equity RatioN/A Current Ratio8.82 Quick Ratio8.82 Sales & Book Value Annual Sales$1.07 million Price / Sales426.37 Cash FlowN/A Price / Cash FlowN/A Book Value$6.67 per share Price / Book1.59Miscellaneous Outstanding Shares43,080,000Free Float18,973,000Market Cap$456.22 million OptionableNot Optionable Beta-0.23 Social Links Key ExecutivesMr. Fred M. Schwarzer J.D. (Age 70)CEO, Pres & Director Comp: $926.9kDr. Lisa L. Decker Ph.D. (Age 54)Chief Bus. Officer Comp: $528.18kDr. Chris H. Takimoto FACP (Age 64)M.D., Ph.D., Chief Medical Officer Comp: $662.28kMr. Misbah Tahir (Age 48)Chief Financial Officer Mr. Steven Weber (Age 47)Sr. VP, Corp. Controller & Principal Accounting Officer Dr. Bruce A. Keyt (Age 70)Chief Scientific Officer Mr. Paul C. GraffagninoVP of Legal AffairsMs. Suzette Tauber (Age 59)Chief HR Officer Dr. Shinyu Chen M.D. (Age 54)Ph.D., Consultant Dr. Angus M. Sinclair Ph.D.Sr. VP of Immuno-OncologyMore ExecutivesKey CompetitorsAnaptysBioNASDAQ:ANABOcular TherapeutixNASDAQ:OCULProcaps GroupNASDAQ:PROCOrganogenesisNASDAQ:ORGOArcutis BiotherapeuticsNASDAQ:ARQTView All CompetitorsInsiders & InstitutionsChris H TakimotoSold 1,259 sharesTotal: $15,498.29 ($12.31/share)Putnam Investments LLCBought 5,510 shares on 5/22/2023Ownership: 0.048%JPMorgan Chase & Co.Bought 2,585 shares on 5/18/2023Ownership: 0.032%State Street CorpBought 3,651 shares on 5/16/2023Ownership: 0.533%Geode Capital Management LLCBought 4,307 shares on 5/16/2023Ownership: 0.460%View All Insider TransactionsView All Institutional Transactions IGMS Stock - Frequently Asked Questions Should I buy or sell IGM Biosciences stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IGM Biosciences in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IGMS shares. View IGMS analyst ratings or view top-rated stocks. What is IGM Biosciences' stock price forecast for 2023? 7 brokerages have issued 12 month price targets for IGM Biosciences' stock. Their IGMS share price forecasts range from $17.00 to $55.00. On average, they anticipate the company's stock price to reach $29.63 in the next year. This suggests a possible upside of 179.7% from the stock's current price. View analysts price targets for IGMS or view top-rated stocks among Wall Street analysts. How have IGMS shares performed in 2023? IGM Biosciences' stock was trading at $17.01 at the start of the year. Since then, IGMS stock has decreased by 37.7% and is now trading at $10.59. View the best growth stocks for 2023 here. When is IGM Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our IGMS earnings forecast. How were IGM Biosciences' earnings last quarter? IGM Biosciences, Inc. (NASDAQ:IGMS) announced its quarterly earnings results on Thursday, March, 30th. The company reported ($1.19) EPS for the quarter, topping analysts' consensus estimates of ($1.53) by $0.34. The firm had revenue of $0.37 million for the quarter, compared to the consensus estimate of $15.27 million. IGM Biosciences had a negative net margin of 14,363.10% and a negative trailing twelve-month return on equity of 74.30%. During the same period in the previous year, the business earned ($1.50) earnings per share. What ETFs hold IGM Biosciences' stock? ETFs with the largest weight of IGM Biosciences (NASDAQ:IGMS) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Nasdaq Future Gen 200 ETF (QQQS), Principal Healthcare Innovators ETF (BTEC), iShares Biotechnology ETF (IBB), ProShares Ultra Nasdaq Biotechnology (BIB) and What other stocks do shareholders of IGM Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other IGM Biosciences investors own include Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), ImmunoGen (IMGN), Plug Power (PLUG), Atreca (BCEL), Carnival Co. & (CCL), Cisco Systems (CSCO), Dropbox (DBX) and Energy Transfer (ET). When did IGM Biosciences IPO? (IGMS) raised $125 million in an initial public offering (IPO) on Wednesday, September 18th 2019. The company issued 7,800,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, Stifel and Guggenheim Securities acted as the underwriters for the IPO. What is IGM Biosciences' stock symbol? IGM Biosciences trades on the NASDAQ under the ticker symbol "IGMS." Who are IGM Biosciences' major shareholders? IGM Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (4.92%), FMR LLC (1.96%), BlackRock Inc. (1.79%), State Street Corp (0.53%), Geode Capital Management LLC (0.46%) and Candriam S.C.A. (0.44%). Insiders that own company stock include Bruce Keyt, Chris H Takimoto, Daniel Shinyu Chen, Fred Schwarzer, George Gauthier, Jakob Haldor Topsoe, Julie Hambleton, M Kathleen Behrens, Michael D Loberg, Misbah Tahir and Redmile Group, Llc. View institutional ownership trends. How do I buy shares of IGM Biosciences? Shares of IGMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is IGM Biosciences' stock price today? One share of IGMS stock can currently be purchased for approximately $10.59. How much money does IGM Biosciences make? IGM Biosciences (NASDAQ:IGMS) has a market capitalization of $456.22 million and generates $1.07 million in revenue each year. The company earns $-221,100,000.00 in net income (profit) each year or ($5.17) on an earnings per share basis. How many employees does IGM Biosciences have? The company employs 192 workers across the globe. How can I contact IGM Biosciences? IGM Biosciences' mailing address is 325 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The official website for the company is igmbio.com. The company can be reached via phone at 650-965-7873. This page (NASDAQ:IGMS) was last updated on 6/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IGM Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.